Improving digital study designs: better metrics, systematic reporting, and an engineering mindset DOI
Viktor von Wyl

The Lancet Digital Health, Год журнала: 2024, Номер 7(1), С. e4 - e5

Опубликована: Дек. 24, 2024

Язык: Английский

From wearable sensor data to digital biomarker development: ten lessons learned and a framework proposal DOI Creative Commons
Paola Daniore, Vasileios Nittas, Christina Haag

и другие.

npj Digital Medicine, Год журнала: 2024, Номер 7(1)

Опубликована: Июнь 18, 2024

Wearable sensor technologies are becoming increasingly relevant in health research, particularly the context of chronic disease management. They generate real-time data that can be translated into digital biomarkers, which provide insights our and well-being. Scientific methods to collect, interpret, analyze, translate from wearables biomarkers vary, systematic approaches guide these processes currently lacking. This paper is based on an observational, longitudinal cohort study, BarKA-MS, collected wearable physical rehabilitation people living with multiple sclerosis (MS). Based experience we discuss ten lessons learned relation biomarker development across key study phases. We then summarize a guiding framework (DACIA) aims informs use for management future research teaching.

Язык: Английский

Процитировано

7

A Digital Solution to Support Medication Adherence and Self-Management in Patients with Cancer: SAMSON Pilot Randomized Controlled Trial (Preprint) DOI Creative Commons
Thu Ha Dang, Nilmini Wickramasinghe, Prem Prakash Jayaraman

и другие.

Опубликована: Авг. 12, 2024

BACKGROUND Medication non-adherence is a serious problem in cancer with potential impact on patients’ health outcomes and healthcare costs. Technology-based medication adherence (MA) interventions are increasingly introduced, yet their evidence of quality effectiveness poor. OBJECTIVE This study aimed to test the acceptability, feasibility, effects SAMSON, digital solution designed support MA self-management cancer. METHODS was two-arm, unblinded, 12-week, pragmatic pilot randomized controlled trial (RCT). Adults who started oral medicines for haematological malignancies within last 12 months were recruited from metropolitan specialised hospital. Participants 1:1 either SAMSON or control arm receive usual care. The included smartphone app which allows prompting individually tailored phone alerts real-time self-care advice, web-based dashboard professionals (HCPs) monitor symptoms, alongside motivational interviewing (MI) teleconsultations delivered by oncology nurses pharmacists scheduled after recruitment at weeks 1, 4, 8 12, patient side-effect self-management. Primary acceptance measured Unified Theory Acceptance Use Technology weeks, predefined rates recruitment, randomization, retention, intervention outcome assessment completion. Secondary comparison clinical self-assessments through online questionnaires, including adherence, toxicity self-management, anxiety-depression-and life, baseline between two arms. Data retrieved tasks completed patients used analysis. RESULTS Thirty-three (78.6% those approached) consented participate trial. Of those, 31 (93.7%) surveys randomised (n=15) arms (n=16). Twenty-eight (90.3%) week-12 (12 16 control). Overall, rated as highly acceptable (13/15; 86.7% usage 14/15; 93.3% MI teleconsultation delivery). They reported that easy-to-use (10/12; 83.3%) helpful improving (6/12; 50%). All HCPs supporting MA. Patients an average 99 over 12-week period (70.7% tasks). Most all five consultations. feasibility measures higher than upper thresholds, except rate responses reminders. CONCLUSIONS results demonstrated acceptable, usable, useful feasible real-life settings. Our next steps involve refining based participants’ feedback, conducting large-scale RCT evaluate its economic effectiveness, exploring commercialisation. CLINICALTRIAL ACTRN12623000472673 INTERNATIONAL REGISTERED REPORT RR2-10.1136/bmjopen-2023-079122

Язык: Английский

Процитировано

0

Real-world patterns in remote longitudinal study participation: A study of the Swiss Multiple Sclerosis Registry DOI Creative Commons
Paola Daniore,

Chuqiao Yan,

Mina Stanikić

и другие.

PLOS Digital Health, Год журнала: 2024, Номер 3(11), С. e0000645 - e0000645

Опубликована: Ноя. 6, 2024

Remote longitudinal studies are on the rise and promise to increase reach reduce participation barriers in chronic disease research. However, maintaining long-term retention these remains challenging. Early identification of participants with different patterns offers opportunity for tailored survey adaptations. Using data from online arm Swiss Multiple Sclerosis Registry (SMSR), we assessed sociodemographic, health-related, daily-life related baseline variables against measures follow-up surveys through multivariable logistic regressions unsupervised clustering analyses. We further explored completion requirements inform future designs. Our analysis included 1,757 who completed a median 4 (IQR 2–8) after maximum 13 possible surveys. Survey start year, age, citizenship, MS type, symptom burden independent driving were significant predictors at baseline. Three clusters emerged, no differences outcomes revealed across clusters. Exploratory assessments suggest trends increased complexity lower rates completion. findings offer insights into characteristics associated remote studies, yet they also highlight influence various unexplored factors outcomes. Future should incorporate additional objective that reflect participants’ individual contexts understand their ability remain engaged adaptations accordingly.

Язык: Английский

Процитировано

0

A Digital Solution to Support Medication Adherence and Self-Management in Patients with Cancer: SAMSON Pilot Randomized Controlled Trial (Preprint) DOI Creative Commons
Thu Ha Dang, Nilmini Wickramasinghe, Prem Prakash Jayaraman

и другие.

JMIR Formative Research, Год журнала: 2024, Номер unknown

Опубликована: Авг. 12, 2024

Medication nonadherence is a serious problem in cancer, potentially impacts patients' health outcomes and care costs. Although technology-based medication adherence (MA) interventions have emerged, evidence supporting their quality effectiveness remains limited. This study tested the acceptability, feasibility, potential effects of Safety Adherence to Medications Self-care Advice Oncology (SAMSON), digital solution designed support MA self-management cancer. A 12-week, 2-arm, unblinded, pragmatic pilot randomized controlled trial was conducted. Adults with hematological malignancies who started oral cancer medicines within last 12 months were recruited from metropolitan specialized hospital 1:1 SAMSON or control (usual care). The included smartphone app tailored alerts real-time self-care advice, web-based dashboard for professionals (HCPs) monitor symptoms, motivational interviewing (MI) teleconsultations delivered by oncology nurses pharmacists at baseline weeks 1, 4, 8, 12. Primary acceptance SAMSON, measured Unified Theory Acceptance Use Technology weeks, predefined rates recruitment, randomization, retention, intervention adherence, outcome assessment completion. Secondary comparison clinical self-assessments through online questionnaires, including toxicity self-management, anxiety depression life, between 2 arms. Data retrieved (Swinburne University Technology) analysed task total 33 patients (79% those approached) consented participate trial. Of those, 31/33 (94%) completed surveys (15/31) arms (16/31). 31 patients, 28 (90%) 12-week (12 16 control). Overall, rated as highly acceptable (13/15, 87% usage; 14/15, 93% MI teleconsultation delivery). They reported that easy use (10/12, 83%) helpful improving (6/12, 50%). All HCPs MA. Patients an average 99 tasks over period (71% scheduled tasks). Most all 5 consultations. feasibility measures higher than upper thresholds, except rate responses reminders. results demonstrated acceptable, usable, useful feasible real-life settings. Our next steps involve refining based on participants' feedback, conducting large-scale evaluate its economic effectiveness, exploring commercialization. Australian New Zealand Clinical Trials Registry ACTRN12623000472673; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385728. RR2-10.1136/bmjopen-2023-079122.

Язык: Английский

Процитировано

0

Improving digital study designs: better metrics, systematic reporting, and an engineering mindset DOI
Viktor von Wyl

The Lancet Digital Health, Год журнала: 2024, Номер 7(1), С. e4 - e5

Опубликована: Дек. 24, 2024

Язык: Английский

Процитировано

0